A/Prof Kumar Gogna

MBBS, DCH, FRCP, FRANZCR
Radiation Oncologist
Refer a patient

Biography

Associate Professor N. Kumar Gogna is a senior radiation oncologist at Radiation Oncology Centres Greenslopes, Redland and Springfield.

Dr Gogna trained as a radiation oncologist at the St Vincent’s Hospital in Sydney and for the last 20 years has been based at the Radiation Oncology Mater Centre in Brisbane.

Dr Gogna is one of the founding directors of the Radiation Oncology Queensland (now known as ROC and part of Icon Group) at the St Andrew’s Hospital in Toowoomba. Over the last nine years Dr Gogna and his colleagues have been passionate about taking oncological services to regional and remote areas of the country.

He is vastly experienced and has special interests in the treatment of prostate and bladder cancers, head and neck tumours and lymphomas. He has expertise in seed implant therapy for the management of early stage prostate cancer and was instrumental in setting up the first seed brachytherapy programme in Queensland.

He is actively involved in research activities especially pertaining to the betterment of treatments for urological cancers through the Trans Tasman Radiation Oncology Group (TROG) in Australia. In addition, Dr Gogna was previously a member of the executive board of the Faculty of Radiation Oncology with the Royal Australia and New Zealand College of Radiologists (RANZCR).

Currently he is actively involved in the teaching and mentoring of trainee registrars in radiation oncology and is an examiner in pathology for the Part II of the fellowship examination held by the RANZCR. Dr Gogna is held in high regard by his colleagues across Australia and New Zealand.

Special Interests

Dr Kumar Gogna accepts referrals for all cancer types, with a special clinical interest in:
  • Head and neck cancer
  • Lymphoma
  • Urological cancer

Icon Locations

Greenslopes View centre
Redland View centre

Visiting Locations

  • Radiation Oncology Mater Centre

Publications

  • Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. (2010). Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Sydney: Cancer Council Australia

  • Denham, J., Joseph, D., Lamb, D., Spry, N., Duchesne, G., & Matthews, J. et al. (2014). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. The Lancet Oncology, 15(10), 1076-1089. http://dx.doi.org/10.1016/s1470-2045(14)70328-6

  • Denham, J., Nowitz, M., Joseph, D., Duchesne, G., Spry, N., & Lamb, D. et al. (2014). Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr. BJU International, n/a-n/a. http://dx.doi.org/10.1111/bju.12497

  • Denham, J., Steigler, A., Joseph, D., Lamb, D., Spry, N., & Duchesne, G. et al. (2015). Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 115(3), 301-307. http://dx.doi.org/10.1016/j.radonc.2015.05.016

  • Denham, J., Wilcox, C., Joseph, D., Spry, N., Lamb, D., & Tai, K. et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. The Lancet Oncology, 13(12), 1260-1270. http://dx.doi.org/10.1016/s1470-2045(12)70423-0

  • Foroudi, F., Pham, D., Rolfo, A., Bressel, M., Tang, C., & Tan, A. et al. (2014). The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 111(2), 316-320. http://dx.doi.org/10.1016/j.radonc.2014.02.015

  • Gogna, N., Baxi, S., Hickey, B., Baumann, K., Burmeister, E., & Holt, T. (2012). Split-Course, High-Dose Palliative Pelvic Radiotherapy for Locally Progressive Hormone-Refractory Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 83(2), e205-e211. http://dx.doi.org/10.1016/j.ijrobp.2011.12.028

  • Hindson, B., Turner, S., Millar, J., Foroudi, F., Gogna, N., & Skala, M. et al. (2012). Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 56(1), 18-30. http://dx.doi.org/10.1111/j.1754-9485.2011.02336.x

  • Morgan, G., Barton, M., Atkinson, C., Millar, J., Gogna, N., & Yeoh, E. (2010). ‘GAP’ in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 54(3), 287-297. http://dx.doi.org/10.1111/j.1754-9485.2010.02172.x

  • Thiruthaneeswaran, N., Turner, S., Milross, C., & Gogna, K. (2014). Promoting a Research Culture among Junior Radiation Oncologists: Outcomes from the Introduction of the Australian and New Zealand Research Requirement in Training. Clinical Oncology, 26(3), 162-173. http://dx.doi.org/10.1016/j.clon.2013.12.007

  • Woo, H., Begbie, S., Gogna, K., Mainwaring, P., Murphy, D., & Parnis, F. et al. (2014). Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. Asia-Pacific Journal of Clinical Oncology, 10(3), 228-236. http://dx.doi.org/10.1111/ajco.12264

View all Doctors

Search